Clinical Trials Logo

Substance-Related Disorders clinical trials

View clinical trials related to Substance-Related Disorders.

Filter by:

NCT ID: NCT02907944 Completed - Clinical trials for Substance-related Disorders

Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation

WHAT-IF?
Start date: September 2016
Phase: N/A
Study type: Interventional

Tobacco, alcohol and opioid use disorders threaten the health of HIV-infected patients. What if evidence-based counseling and medication treatments for tobacco, alcohol and opioid use disorders (herein refered to as addiction treatments) were routinely provided in HIV clinics? Implementation Facilitation is an established strategy to increase the uptake of evidence-based treatments. Our goal is to evaluate the impact of Implementation Facilitation on the use of addiction treatments in four large HIV clinics. The purpose of the WHAT-IF study is: Aim 1. Among key stakeholders, to use quantitative and qualitative (mixed) methods to identify the site-specific evidence, context and facilitation-related barriers and facilitators to the integration of addiction treatments to help tailor an Implementation Facilitation for each clinic. Aim 2. To evaluate the impact of Implementation Facilitation on: 2a: Organizational readiness to deliver addiction treatments 2b: Provider readiness to deliver addiction treatments 2c: Provision of addiction treatments 2d: Changes in organizational models of care used to deliver addiction treatments Aim 3. To evaluate the impact of Implementation Facilitation on antiretroviral therapy receipt, HIV viral suppression, VACS Index, and retention in HIV care among patients eligible for addiction treatment.

NCT ID: NCT02906215 Completed - HIV Clinical Trials

Mobile Application to Improve Care Coordination Among HIV Clinic and Substance Use Treatment Providers

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Many people living with HIV use illicit drugs and require treatment for both HIV and drug use, however, many barriers exist which prevent integration of dual care services. This study will develop a novel intervention aimed at the provider-level which will combine an evidence-based training model with use of mobile technology to improve care coordination between providers at HIV clinics and substance use treatment facilities. If proven effective, this intervention may be widely disseminated and easily implemented into existing clinic structures, thereby improving care coordination among providers and linkage to dual treatment for HIV-infected people who use drugs.

NCT ID: NCT02903251 Completed - Clinical trials for Substance-Related Disorders

Oxytocin and Alcohol Withdrawal and Dependence

Start date: October 2016
Phase: Phase 3
Study type: Interventional

This study evaluates the effect of oxytocin nasal spray on alcohol withdrawal and dependence in adults admitted for detoxification of alcohol, and during the following 4 weeks in an outpatient setting. Half of the participants will receive oxytocin nasal spray, the other half placebo nasal spray.

NCT ID: NCT02902081 Completed - Drug Addiction Clinical Trials

Cannabidiol and Emotional Stimuli

CAS
Start date: February 2013
Phase: N/A
Study type: Interventional

The purpose of this research is to examine the effect of cannabidiol (CBD), a cannabinoid compound found in marijuana, on responses to emotional stimuli. Both preclinical and clinical studies indicate that CBD may act to reduce anxiety without excessive sedative side-effects. Thus the investigators hypothesize that CBD may reduce responses specifically to negative emotional and social stimuli, including pictures and emotional faces, without altering responses to positive stimuli. To examine this, the investigators will administer placebo, 300mg, 600mg, and 900mg CBD to healthy normal adults in a double-blind within-subjects study. The investigators will measure subjective and subtle physical responses to positive and negative stimuli using measures that have been characterized with classic anxiety-reducing drugs and drugs of abuse. Further, the investigators will examine whether CBD-induced changes in these measures of emotional response relate to changes in actual behavior in a controlled social interaction. These results will allow the investigators to examine the potential usefulness of CBD as an anxiety-reducing drug, and suggest mechanisms by which CBD may reduce anxiety.

NCT ID: NCT02892110 Completed - Clinical trials for Substance Use Disorder

Varenicline Treatment for Cannabis Use Disorder

Start date: February 13, 2017
Phase: Phase 2
Study type: Interventional

Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.

NCT ID: NCT02888249 Completed - Clinical trials for Tobacco Use Disorder

Behavioral Economic Purchasing Decisions for Cigarettes of Varied Compositions

Start date: August 25, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the abuse liability of cigarettes with altered composition (cigarettes differing in composition; e.g., tar levels, amount of sugar, casings) is reduced relative to standard composition cigarettes.

NCT ID: NCT02872467 Completed - Pregnancy Clinical Trials

Prenatal Cocaine, Nasal Oxytocin, and Maternal Psychophysiology

NOX
Start date: May 2016
Phase: Phase 1
Study type: Interventional

The purpose of this research is to study the effects of nasal oxytocin administration on maternal behaviors that may be influenced by cocaine use during pregnancy. 32 mothers with prenatal use of cocaine during the current pregnancy will be studied at 3-6 months postpartum, when they will complete 3 study visits, a 2-week double-blind trial of twice daily nasal spray (oxytocin or placebo) and 4 telephone interviews. All information collected is confidential.

NCT ID: NCT02861820 Completed - Clinical trials for Substance Use Disorder

Functional Connectivity Changes During Early Recovery as a Marker for Relapse

Start date: July 1, 2015
Phase:
Study type: Observational

The study purpose is to examine whether there are structural or functional differences in the brains of individuals who use cocaine or amphetamines as opposed to control participants who have never used cocaine or amphetamines. More specifically, it will allow the investigator to see how the brain changes once people get sober and how those changes relate to successful recovery. This study will allow the investigator to examine the interaction between cocaine/amphetamines and impulsivity (meaning to act on impulse rather than thought). Results from this study will inform new biologically-based interventions to compliment existing treatment programs, in the hope of leading the field in a new direction.

NCT ID: NCT02846649 Completed - Clinical trials for Substance-Related Disorders

A Text Messaging Program to Help Prevent Early Opioid Relapse

PIER1
Start date: August 2016
Phase: N/A
Study type: Interventional

The objective is to determine feasibility and acceptability of a text message (SMS)-based relapse prevention intervention as measured through: (1) study retention and SMS query completion rates and (2) participant ratings of PIER1 interest, perceived efficacy, and ease of use. Methods: A mixed methods study of adult (age >=18) ED patients who seek treatment for opioids and have evidence of dependence based on Rapid Opioid Dependence Screen (RODS) score of >3 and are being discharged to outpatient (community) resources. All participants receive standard of care in the ED, complete a baseline web survey, are asked to text with us for at least 7 days (up to a max of 28 days) and are asked to complete a follow-up phone call between day 8 and 14. Investigators expect preliminary findings to support a relapse prevention intervention delivered through SMS. Based on feedback from this mixed methods study, investigators plan to test a refined SMS program in a randomized trial.

NCT ID: NCT02845453 Completed - Bipolar Disorder Clinical Trials

Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation

Start date: January 20, 2017
Phase: Phase 4
Study type: Interventional

This study proposes to use quetiapine as an adjunct treatment to treatment as usual to improve both substance use disorder (SUD) and mood symptoms in youth with SUD and severe mood dysregulation (SMD). This is a randomized, double blind placebo controlled parallel design study. Youth with symptoms of mood dysregulation and active substance use that meets criteria for a SUD will be randomized to adjunct treatment with quetiapine or placebo. The investigators hypothesize that treatment with quetiapine will lead to a reduction in substance use, improvement in mood, and lead to greater engagement in outpatient treatment.